October 1, 2020, 07.05 PM

Regulators in the UK, Brazil, India and South Africa have allowed AstraZeneca to resume its clinical trials there.

The FDA, however, wants to determine whether similar side effects emerged in trials of other vaccines designed by AstraZeneca's Covid-19 vaccine partner, researchers at Oxford University, the sources said.

Read also: Indonesia to Make $223.6 Million Down Payment for Covid-19 Vaccine

That does not mean the agency believes there were safety issues associated with any of these vaccines, they added.

"It just shows that the FDA is being thorough," said one of the sources.

Further complicating the situation is that the data requested by the FDA is in a different format than what the US regulator requires, two of the sources said.

The FDA declined to comment on discussions involving an experimental product. Oxford did not respond to requests for comment.

AstraZeneca, in a statement, said: "We are continuing to work with the FDA to facilitate review of the information needed to make a decision regarding resumption of the US trial."

Viral vector

All of the vaccines it wants to review use a modified adenovirus as vectors to safely deliver genetic material from the target illnesses — flu, Middle East Respiratory Syndrome, and other diseases — into the body to stimulate an immune system response to fight future infection.

Page:


Latest Video Video Lainnya >

Comment wisely and responsibly. Comments are entirely the responsibility of the commentator as regulated in the ITE Law
Report
Thank You! We have received your report. We will remove comments that conflict with the Community Guidelines and the ITE Law.

More Headlines

News
November 28, 2022, 05.16 PM

Death Toll from Indonesia Quake Rises to 321

News
November 24, 2022, 05.14 PM

Malaysia: Opposition Leader Anwar Ibrahim Named PM

Close Ads